MAINZ BIOMED B.V. EO 1 news, videos and press releases - Page 6
For more news please use our advanced search feature.
MAINZ BIOMED B.V. EO 1 - More news...
MAINZ BIOMED B.V. EO 1 - More news...
- Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
- Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
- Mainz Biomed Provides Third Quarter 2022 Update
- Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
- Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board
- Mainz Biomed Reports First Half 2022 Financial Results
- Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference
- Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board
- Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates
- Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development
- Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board
- Mainz Biomed Today to Provide Corporate Update for First Half of 2022
- Mainz Biomed Provides Corporate Update for First Half of 2022
- Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
- Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission
- Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance
- Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
- Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference
- Mainz Biomed to Host Key Opinion Leader Event at DDW 2022
- Mainz Biomed Provides Product Development Update on PancAlert
- Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer
- Mainz Biomed Announces First Quarter 2022 Results
- Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert’s Pivotal Clinical Trial
- Mainz Biomed to Ring Nasdaq Stock Market Closing Bell
- Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study
- Mainz Biomed Announces Year End 2021 Results
- Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month
- Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert
- Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach
- Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board
